Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights Business Wire Data from two positive Phase 3 trials demonstrated rapid onset of effect and durable benefit through at least 6 months, further validating COMP360’s potential to establish a new standard of care in TRD COMP360 has a highly differentiated clinical profile and is expected to be a blockbuster opportunity, if approved Rolling NDA submission and initial review underway and final submission expected to be completed in Q4 Commercial launch expected in first half of 2027 COMP360 expected to fit seamlessly into current treatment infrastructure Late-stage PTSD trial underway Strong cash position of $433 million at the end of second quarter, providing cash well beyond launch and into 2028 Compass management will host a conference call on August 5 at 8:00 am ET
How the boss of Zilch became UK fintech’s power broker Fintech Last year, Zilch founder Philip Belamant sat down with then-boss of Monzo, TS Anil. As the two friends caught up, Belamant was fizzing with ideas to turn his $2bn British fintech into a global powerhouse, according to sources familiar with the matter. Not long ago, Zilch had set up shop across the pond, and Belamant [...]
Meet the woman who won $500,000 playing Candy Crush Life&Style Candy Crush is a garish game that can make winners incredibly rich. Anna Moloney attends the world finals and meets the new champion.
Janus Henderson Announces Receipt of Required Regulatory Approvals and Client Consents Following Resounding Shareholder Approval of the Trian and General Catalyst Take-Private Transaction June 18, 2026 Anticipates June 30, 2026 Closing Date
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights May 13, 2026 FDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 data CNPV awarded for COMP360 in TRD, further accelerating momentum 26-week (Part B) data from COMP006, expected in early Q3 2026 Final NDA submission on track for Q4, aligned with Company’s previously defined accelerated timing to be launch ready by end of year Successful financing and warrant exercises resulted in strong cash position of $466 million at end of first quarter, providing cash runway well beyond launch and into 2028
Aldi snaps up abandoned London psychiatric hospital to turn it into supermarket April 15, 2026 Aldi has snapped up an abandoned London psychiatric hospital, City AM can reveal, in the latest sign discount supermarkets are getting increasingly creative in their search to acquire land to expand their UK footprint. The German grocer, which has over 1,000 stores in the UK but hopes to increase this by as many as 500, [...]
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights March 24, 2026 COMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect in treatment resistant depression (TRD), with a generally well-tolerated and safe profile Across three large trials in TRD, including two positive Phase 3 studies, COMP360’s differentiated profile is redefining rapidity and durability for TRD patients and demonstrating a consistent level of clinical effect that has never been achieved before Compass will meet with the FDA to confirm alignment on a rolling submission and review, and expects to complete the NDA submission in Q4 Compass is rapidly advancing commercial readiness plans and expects COMP360 will fit seamlessly across diverse healthcare settings at launch Phase 2b/3 trial in PTSD initiating, following FDA acceptance of IND application Successful $150 million financing in February and exercise of $200 million in warrants extends cash runway into 2028
Compass Pathways Announces Pricing of $150 Million Public Offering February 23, 2026 Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants [...]
Hamilton Lane’s Erik Hirsch: We’re seeing a private credit witch hunt February 17, 2026 Depending on which central banking chief you talk to, the burgeoning private credit industry is either a cause of insomnia, a “dark corner” of finance or an arcane lending practice whose participants are behaving like bankers in the run-up to the global financial crisis. To Hamilton Lane boss Erik Hirsch, though, it is simply an [...]
Why the Tory Party tried to persuade Karren Brady to run for London mayor February 10, 2026 The Tories need a political heavyweight to come forward and run for mayor. We once tried but to no avail, writes Giles Kenningham